Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1986-06-16
1989-08-29
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514824, A61K 31495
Patent
active
048617784
ABSTRACT:
A compound having the structural formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen with the provisos that if R.sup.2, R.sup.3 and R.sup.4 are hydrogen, then R.sup.1 is not methyl, n-propyl or phenyl substituted with methyl in the ortho or para position; if R.sup.1, R.sup.2 and R.sup.3 are hydrogen then R.sup.4 is not hydrogen, methyl or methoxy; and if R.sup.1 and R.sup.2 are both n-propyl or n-butyl then R.sup.3 and R.sup.4 are not both hydrogen. These compounds demonstrate utility as hypolipidemic agents.
The present invention is also directed to a process for controlling hyperlipidemia in mammals comprising treating mammals with a hyperlipidemia controlling effective amount of a compound having the above-identified structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen.
Yet another aspect of the present invention is embodied in a pharmaceutical composition comprising a compound having the above structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen and a pharmaceutically acceptable carrier therefor.
REFERENCES:
patent: 2420702 (1948-05-01), Drewitt et al.
patent: 2453578 (1948-11-01), Lacey et al.
patent: 3433641 (1969-03-01), Margot
patent: 3497512 (1970-02-01), Hofer et al.
patent: 3864343 (1975-02-01), Inoue et al.
patent: 3870792 (1975-03-01), Inoue et al.
patent: 3963716 (1976-06-01), Inoue et al.
patent: 4226993 (1980-10-01), Buckler et al.
patent: 4293553 (1981-10-01), Ishikawa et al.
Buu-Hoi et al., Rec. Trav. Chim., vol. 70, 1099-1104 (1951).
Offe et al., Zeit. Natur., vol. 7b, 446-462 (1952).
White et al., J. Org. Chem., 34:2462-2468 (1968).
Chapman, Jr. James M.
Hall Iris H.
Wyrick Steven D.
Kearse R.
Research Corporation
Robinson Douglas W.
LandOfFree
2,3-dihydrophthalazine-1,4-diones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3-dihydrophthalazine-1,4-diones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3-dihydrophthalazine-1,4-diones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2238440